Insmed
INSM
Market cap $20.3B

107.06 USD

+2.06

1.96%

Updated Jul 30, 1:28 PM EDT

1 day

1.96%

5 days

2.87%

1 month

6.38%

3 months

48.69%

6 months

40.33%

Year to date

53.05%

1 year

46.84%

5 years

295.93%

10 years

300.37%

About: Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Employees: 1,271

Healthcare Biotechnology

0

Funds holding %

of 7,323 funds

0

Analysts bullish %

of 11 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

23% more repeat investments, than reductions

Existing positions increased: 183 | Existing positions reduced: 149

14% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 49

14% more capital invested

Capital invested by funds: $13.3B [Q4 2024] → $15.2B (+$1.87B) [Q1 2025]

7% more funds holding in top 10

Funds holding in top 10: 29 [Q4 2024] → 31 (+2) [Q1 2025]

1.68% more ownership

Funds ownership: 107.61% [Q4 2024] → 109.29% (+1.68%) [Q1 2025]

0% more funds holding

Funds holding: 434 [Q4 2024] → 434 (+0) [Q1 2025]

50% less call options, than puts

Call options by funds: $73M | Put options by funds: $145M

See Fund Rankings

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$105

2%

downside

Avg. target

$112

5%

upside

High target

$130

21%

upside

11 analyst ratings

11 positive

100%

0 neutral

0%

0 negative

0%

Wells Fargo Tiago Fauth	21%upside $130	Overweight Maintained	22 Jul 2025
Morgan Stanley Matthew Harrison	1%upside $108	Overweight Maintained	17 Jul 2025
JP Morgan Jessica Fye	4%upside $111	Overweight Maintained	8 Jul 2025
Goldman Sachs Andrea Tan	5%upside $112	Buy Maintained	11 Jun 2025
Mizuho Graig Suvannavejh	3%upside $110	Outperform Maintained	11 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about INSM published over the past 30 days

Investors Business Daily

Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?

Insmed stock is soaring as it approaches the potential approval of its second drug. CEO Will Lewis calls it a "skeleton key.

Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?

Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025

BRIDGEWATER, N.J. , July 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2025 financial results on Thursday, August 7, 2025.

Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025

CNBC Television

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.

It is time for a move higher in biotech, says Mizuho's Jared Holz

Russell Rebalance: 3 Stocks Ready to Move Higher

Investors pay close attention to the quarterly rebalancing of the S&P 500 index for good reason. First, the stocks in the S&P 500 make up approximately 80% of the total U.S. equity market.

Russell Rebalance: 3 Stocks Ready to Move Higher

Is Insmed Stock Overvalued After The 45% Jump?

Insmed Inc (NASDAQ: INSM) was nothing short of a powerhouse last month, soaring 45%, while the S&P 500 index rose 3% in the same timeframe. What's driving this surge?

Is Insmed Stock Overvalued After The 45% Jump?

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it priced an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $96.00 per share.

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

Insmed Announces Proposed $650 Million Public Offering of Common Stock

BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it intends to offer and sell $650 million of shares of its common stock in an underwritten public offering.

Insmed Announces Proposed $650 Million Public Offering of Common Stock

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

Insmed Incorporated INSM on Tuesday released topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension.

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

Zacks Investment Research

Insmed Stock Jumps 29% on Encouraging PAH Study Results

INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.

Insmed Stock Jumps 29% on Encouraging PAH Study Results

CNBC Television

Insmed CEO Will Lewis on stock surge after positive trial results

Will Lewis, Insmed Chair & CEO, joins 'Fast Money' to talk its recent trial results for Pulmonary Arterial Hypertension therapy, the stock reaction, and more.

Insmed CEO Will Lewis on stock surge after positive trial results

See News Rankings

Charts implemented using Lightweight Charts™